SEC Form 4 · accession 0001144204-18-033929
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wei-Wu He
Director · 10% Owner
Period of report
Jun 11, 2018
Accepted (ET)
Jun 12, 2018 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $3.22 | Jun 11, 2018 | A | 1,000,000 | A | Mar 13, 2019 | Mar 13, 2028 | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1The option grant was approved by the Board of Directors on March 13, 2018, subject to stockholder approval of the option grant. The Company's stockholders approved the option grant on June 11, 2018. All of the options will vest and become exercisable on the first anniversary date of the grant.